EXELIXIS INC
10-Q, EX-27.1, 2000-08-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: EXELIXIS INC, 10-Q, EX-10.21, 2000-08-14
Next: AMERICAN ARCHITECTURAL PRODUCTS CORP, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE>      5
<LEGEND>       THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL  INFORMATION
               EXTRACTED FROM  THE QUARTERLY REPORT PURSUANT  TO SECTION
               13 OR 15(d) OF THE SECURITIES  EXCHANGE  ACT  OF 1934 FOR
               THE QUARTERLY PERIOD ENDED JUNE 30, 2000.
</LEGEND>
<MULTIPLIER> 1,000

<S>                                                       <C>
<PERIOD-TYPE>                                             6-MOS
<FISCAL-YEAR-END>                                         DEC-31-2000
<PERIOD-START>                                            JAN-01-2000
<PERIOD-END>                                              JUN-30-2000
<CASH>                                                       51,418
<SECURITIES>                                                 74,621
<RECEIVABLES>                                                   936
<ALLOWANCES>                                                      0
<INVENTORY>                                                       0
<CURRENT-ASSETS>                                            128,891
<PP&E>                                                       16,247
<DEPRECIATION>                                                    0
<TOTAL-ASSETS>                                              146,887
<CURRENT-LIABILITIES>                                        13,790
<BONDS>                                                           0
                                             0
                                                       0
<COMMON>                                                         45
<OTHER-SE>                                                  113,087
<TOTAL-LIABILITY-AND-EQUITY>                                146,887
<SALES>                                                      11,567
<TOTAL-REVENUES>                                             11,567
<CGS>                                                             0
<TOTAL-COSTS>                                                     0
<OTHER-EXPENSES>                                             31,515
<LOSS-PROVISION>                                                  0
<INTEREST-EXPENSE>                                             (326)
<INCOME-PRETAX>                                             (18,260)
<INCOME-TAX>                                                      0
<INCOME-CONTINUING>                                         (18,260)
<DISCONTINUED>                                                    0
<EXTRAORDINARY>                                                   0
<CHANGES>                                                         0
<NET-INCOME>                                                (18,260)
<EPS-BASIC>                                                 (0.90)
<EPS-DILUTED>                                                 (0.90)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission